Enhancing Mesenchymal Stromal Cell Immunomodulation for Treating Conditions Influenced by the Immune System

Table 1

Clinical trials of MSCs on diseases mediated by the immune system.

Trial no.	Phase	Commencement year	Targeted disease	Status	Patient enrollment ()	Country
NCT00447460	I/II	2007	Graft vs. host disease (GvHD)	Completed [100]	15	Spain
NCT01522716	I	2011		Unknown (NRP)	11	Sweden
NCT01764100	I	2013		Completed [101]	40	Italy
NCT02032446	I/II			Recruiting	47 (estimated)
NCT02291770	III	2014		Unknown (NRP)	130 (estimated)	China
NCT02055625	I/II			Suspended (NRP)	11	Sweden
NCT02359929	I	2015		Recruiting	24 (estimated)	USA
NCT01741857	I/II		Systemic lupus erythematosus (SLE)	Completed [102]	40	China
NCT03171194	I			Active, not recruiting	6 (estimated)	USA
NCT03673748	II	2019	SLE/lupus nephritis	Not yet recruiting	36 (estimated)	Spain
NCT00781872	I/II	2006	Multiple sclerosis (MS)	Completed [103]	20	Israel
NCT00395200	I/II	2008		Completed [104, 105]	10	UK
NCT01730547	I/II	2013		Unknown	15 (estimated)	Sweden
NCT02495766	I/II	2015		Unknown	8 (estimated)	Spain
NCT03799718	II	2019		Not yet recruiting	20 (estimated)	USA
NCT02893306	II	2012	Type 1 diabetes mellitus (T1DM)	Unknown (NRP)	10	Chile
NCT02940418	I	2017		Recruiting	20 (estimated)	Jordan
NCT03406585	I/II			Recruiting	24 (estimated)	Sweden
NCT02249676	II	2013	Devic syndrome/neuromyelitis optica	Completed	15	China
NCT01659762	I	2012	Crohn’s disease	Completed [106]	16	USA

NRP: no results posted.